Fallopian tube endometrioid tumor
diseaseOn this page
Also known as endometrium neoplasm of fallopian tubefallopian tube endometrioid neoplasmfallopian tube endometrium neoplasm
Summary
Fallopian tube endometrioid tumor (MONDO:0021576) is a cancer and 4 clinical trials. Top therapeutic interventions include tremelimumab. A subtype of fallopian tube neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | fallopian tube endometrioid tumor |
| Mondo ID | MONDO:0021576 |
| NCIT | C40111 |
| UMLS | C1517113 |
| MedGen | 274486 |
| Anatomy (UBERON) | UBERON:0003889 |
| Is cancer (heuristic) | yes |
Also known as: endometrium neoplasm of fallopian tube · fallopian tube endometrioid neoplasm · fallopian tube endometrioid tumor · fallopian tube endometrium neoplasm
Disease family
This is a subtype of fallopian tube neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › fallopian tube disorder › fallopian tube neoplasm › fallopian tube endometrioid tumor
Related subtypes (4): fallopian tube benign neoplasm, fallopian tube cancer, fallopian tube mucinous tumor, fallopian tube germ cell tumor
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04575935 | PHASE3 | RECRUITING | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial |
| NCT04034927 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer |
| NCT03685695 | PHASE2 | COMPLETED | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT02111941 | EARLY_PHASE1 | COMPLETED | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TREMELIMUMAB | 4 | 1 |
Related Atlas pages
- Drugs: Tremelimumab